Drug intelligence / Profile preview

Measles virus (Schwarz strain)

Development stage: Phase 2
Lead developer: Mayo Clinic
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Subcutaneous, Intramuscular, Inhalation

Overview

MV is an oncolytic attenuated measles virus, specifically the Schwarz strain. It functions as an antitumor virotherapy by inducing tumor cell lysis and stimulating an antitumor immune response.

Targets

SLAMF1 (SLAM family member 1)CD46 (CD46 Molecule)PVRL4 (Nectin cell adhesion molecule 4)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Measles virus (Schwarz strain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Measles virus (Schwarz strain).